SOST

SOST 분자 정보

영어 이름Sclerostin시판 약물 수1
임상 약물 수6표적 별명Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
최고 연구 개발 단계Approved
영어 이름Sclerostin
표적 별명Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
시판 약물 수1
임상 약물 수6
최고 연구 개발 단계Approved

SOST 제품 목록

  • 속성

    Protein (2)

  • 제품 라이브러리

    온라인 (2)

  • Human (2)

  • 태그

    His Tag (2)

  • 마커

    Unconjugated (1)Biotin-labeled (1)

SOST분자 배경

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST분자 별명

SOST,VBCH

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
SetrusumabUX143; NOV-3; MOR-05813; BPS-804Phase 3 ClinicalMorphosys Ag, Novartis Pharma AgBone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic
상세
AGA-2115AGA2115; AGA-2115Phase 2 ClinicalAngitia Biopharmaceuticals (Guangzhou) LtdOsteogenesis Imperfecta
상세
AGA-2118AGA-2118Phase 2 ClinicalAngitia Biomedicines LtdOsteoporosis; Osteoporosis, Postmenopausal
상세
ResugosbartSHR-1222Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co LtdOsteoporosis; Osteoporosis, Postmenopausal
상세
Romosozumab biosimilar(Zhuhai Federation Biomedicine)Phase 1 ClinicalZhuhai Federation Biomedicine Co LtdOsteoporosis, Postmenopausal
상세
BlosozumabTST002; LY-2541546; TST002-IgG4Phase 1 ClinicalEli Lilly And CompanyOsteoporosis; Osteoporosis, Postmenopausal
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
RomosozumabCDP-7851; AMG-785ApprovedEvenity, EVENITYJapanOsteoporosisAmgen Inc2019-01-08Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호